⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24800406 | 0.90 | HDAC8 (0.42) | — | |
| Hydrochloric Acid SCHEMBL27035814 | 0.83 | KDM1A (0.55) | — | |
| SCHEMBL31536252 | 0.81 | TGFBR1 (0.37) | — | |
| SCHEMBL31356844 | 0.77 | MAPT (0.38) | — | |
| SCHEMBL27704118 | 0.75 | — | — | |
| SCHEMBL31644106 | 0.74 | AKR1C3 (0.36) | — | |
| SCHEMBL5783757 | 0.73 | KDM1A (0.51) | — | |
| SCHEMBL7828623 | 0.73 | — | — | |
| SCHEMBL17925492 | 0.72 | PDE4A (0.39) | — | |
| SCHEMBL27686852 | 0.72 | CHRNB2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| US-20230065745-A1 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2023-03-02 | — | — | US | disclosed |
| WO-2021110009-A1 | NOVEL AURORA KINASE INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2021-06-10 | — | — | WO | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| CN-101472902-A | Novel piperazine compounds and their use as HCV polymerase inhibitors | JAPAN TOBACCO INC (JP) | 2009-07-01 | — | — | CN | disclosed |
| CN-101426486-A | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORP (US) | 2009-05-06 | — | — | CN | disclosed |
| EP-1957058-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2008-08-20 | — | — | EP | disclosed |
| CN-101027295-A | Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders | SCHERING CORP (US) | 2007-08-29 | — | — | CN | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1773821-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060252778-A1 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | MERCK SHARP & DOHME CORP. | 2006-11-09 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |